---
subject: FDA Alert - Recall - Activase (alteplase) 100mg by Genentech - Lack of Sterility Assurance
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>
		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://blog.drugs.com/wp-content/uploads/2018/02/logo-ddc.jpg" width="211" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right" valign="middle">
					<span class="header-title">FDA Medwatch Alert</span><br>
					<span class="header-sub-title">December 19, 2017</span>
				</p>
			</columns>
		</row>
	</container>
</wrapper>

<container>

	<row class="row-trim-columns">
		<columns small="12">
			<spacer size="30"></spacer>
		</columns>
	</row>

	<row class="row-trim-columns">
	  <columns small="7" large="8" valign="middle">
	    <h2 class="header-trim">New FDA Medwatch Alert</h2>
	    <p class="sub-header text-muted">December 19, 2017</p>
	  </columns>
	  <columns small="5" large="4" valign="top">
	    <img class="logo-medwatch small-float-center" src="https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm408715.png" width="154" height="60" alt="">
	  </columns>
	</row>

	<row>
		<columns small="12">
			<spacer size="8"></spacer>
			<h3><a href="#">Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication - Retained in Body; New Class Warnings</a></h3>
			<p><strong>Audience:</strong> Radiology, Health Care Professional, Patient.<br/>
			<strong>ISSUE:</strong> FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patientsâ€™ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>
			<p class="text-muted"><strong>Sent to subscribers of:</strong> gadobenate dimeglumine systemic, gadodiamide systemic, gadopentetate dimeglumine systemic, gadoteridol systemic, gadoversetamide systemic, gadoxetate disodium systemic, gadofosveset trisodium systemic, gadobutrol systemic, gadoterate meglumine systemic, Diagnosis and Investigation</p>
			<button href="#" class="radius btn-offset">Read More</button>
		</columns>
	</row>

</container>

{{> footer }}